A case study in differing approaches to reimbursement approval in Europe and the US.
Does Real World Evidence Matter in Health Technology Assessments?
pharmaphorum recently published an article written by our Founder and CEO Yin Ho and Associate Data Analyst Daniel Liden: "Sovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?"
Context Matters is in the news again! This time with our analysis on value assessments by UK's National Institute for Health and Care Excellence (NICE) for cancer medicines.
Context Matters data cited in the Wall Street Journal! Ed Silverman recently spoke with PhRMA's Randy Burkholder, who noted that between 2007 and 2013, cancer medicines were more than three times as likely to receive unfavorable recommendations from UK agency NICE, as compared with other drugs.
PharmaPhorum recently published an article written by our Founder and CEO Yin Ho and Associate Director of Data and Analytics Rachel Jao, "Overcoming the Market Access Hurdle through Better Planning of Clinical Trials." The article points out that though regulatory approval is still a key step in getting a drug to market, it no longer guarantees market access. The authors discuss how clinical-trial design and the implications on reimbursement can help companies make better use of their resources and expedite the path to a successful drug launch.
Managed Care recently did an article about our study on the use of the terms "Effectiveness" and "Efficacy" and how they are often used interchangeably or even misused.
Pharmalot did a piece recently on our study about the use of the terms "Efficacy" and "Effectiveness" when making reimbursement decisions. Our study focused on the differences in the terms and how they are often used interchangably in the industry.
Health Tech Zone did a recent article on our study comparing the value of clinical outcomes as compared to Health Technology Assessments (HTAs). Our study focused on the differences between the two and how they affect reimbursement decisions.